- Home
- IMCR vs NUV Comparison
IMCR vs NUV Comparison
Compare IMCR & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- NUV
- Stock Information
- Founded
- IMCR 2008
- NUV 1987
- Country
- IMCR United Kingdom
- NUV United States
- Employees
- IMCR N/A
- NUV N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- NUV Trusts Except Educational Religious and Charitable
- Sector
- IMCR Health Care
- NUV Finance
- Exchange
- IMCR Nasdaq
- NUV Nasdaq
- Market Cap
- IMCR 1.7B
- NUV 1.8B
- IPO Year
- IMCR 2021
- NUV N/A
- Fundamental
- Price
- IMCR $35.17
- NUV $8.52
- Analyst Decision
- IMCR Buy
- NUV
- Analyst Count
- IMCR 10
- NUV 0
- Target Price
- IMCR $58.13
- NUV N/A
- AVG Volume (30 Days)
- IMCR 250.5K
- NUV 464.9K
- Earning Date
- IMCR 08-07-2025
- NUV 01-01-0001
- Dividend Yield
- IMCR N/A
- NUV 3.96%
- EPS Growth
- IMCR N/A
- NUV N/A
- EPS
- IMCR N/A
- NUV N/A
- Revenue
- IMCR $333,581,000.00
- NUV N/A
- Revenue This Year
- IMCR $26.82
- NUV N/A
- Revenue Next Year
- IMCR $8.15
- NUV N/A
- P/E Ratio
- IMCR N/A
- NUV N/A
- Revenue Growth
- IMCR 25.75
- NUV N/A
- 52 Week Low
- IMCR $23.15
- NUV $7.86
- 52 Week High
- IMCR $40.88
- NUV $9.08
- Technical
- Relative Strength Index (RSI)
- IMCR 53.52
- NUV 40.04
- Support Level
- IMCR $32.20
- NUV $8.45
- Resistance Level
- IMCR $37.63
- NUV $8.63
- Average True Range (ATR)
- IMCR 1.21
- NUV 0.06
- MACD
- IMCR 0.03
- NUV -0.02
- Stochastic Oscillator
- IMCR 53.90
- NUV 20.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.